– USA, NJ – Ceptur Therapeutics, Inc., a biotechnology company today announced the appointment of Dr. Romesh Subramanian (Ph.D.) to its Board of Directors, bringing over two decades of experience in the biopharmaceutical industry, including in the founding and leadership of several RNA medicines companies as well as in drug discovery research.
About Dr. Romesh Subramanian
Dr. Romesh Subramanian is the founder of Dyne Therapeutics where he served as CEO and CSO from 2018-to 2021. Before Dyne, Dr. Subramanian led new modality research at Alexion Pharmaceuticals, Inc., focusing on nucleic acid, antibody, and enzyme replacement therapies. Dr. Subramanian further co-founded RaNA Therapeutics, now Translate Bio. Before RaNA, he held positions of increasing responsibility at Pfizer and Thrasos Therapeutics. Dr. Subramanian has served as an entrepreneur-in-residence at Atlas Ventures, an advisor to multiple Venture Capital groups, and currently serves on the advisory board of the Harvard Medical School Initiative for RNA Medicine.
“I am delighted to join Ceptur Therapeutics’ Board of Directors as we develop a novel RNA modality to control gene expression”, said Dr. Subramanian. “I look forward to working closely with the Board and the leadership team to develop U1 Adaptor therapeutics that control gene expression at the pre-mRNA level, enabling a novel class of medicines to benefit patients.”
He holds a bachelor’s degree from Loyola College, a master’s degree from Duke University, and a Ph.D. from Emory University.
About Ceptur Therapeutics, Inc.
Ceptur Therapeutics is building a leading RNA medicines company dedicated to advancing therapeutics for persons with genetically-defined diseases. With its proprietary U1 Adaptor platform, Ceptur is developing targeted oligonucleotides for gene silencing and RNA editing applications; its medicines are designed to overcome limitations in delivery to extrahepatic tissues that are seen with other approaches. Ceptur has a broad portfolio of therapeutic programs for CNS, malignant hematology, and immunology indications.
For more information: https://cepturtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.